BioCentury on BioBusiness,
Letter to BioCentury: BIO initiatives to improve access to the capital markets
Related tables, figures and sidebars
Letter to BioCentury: BIO on capital access
Monday, April 28, 2014
Industry Organization (BIO) is a strong supporter of effective capital
markets, and we hope the April 14 guest commentary, "Reducing the Burden
of Disclosure," will draw attention to these important issues. It is
critically important for innovative biotechnology companies that do not yet
have product revenue to focus investor dollars on the search for cures and
breakthrough medicines rather than divert these funds for cumbersome disclosure
We were very supportive of the
Jumpstart Our Business Startups (JOBS) Act, and continue to be deeply engaged
in its implementation. In the two years since its passage, more than 80 biotech
companies have gone public using provisions included within the JOBS Act.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]